Ex vivo removal of IgE in atopic asthma by extracorporeal plasmoimmunoadsorption (EPIA): development of a clinical adsorbent.
We have developed an immunoadsorbent (IA) for ex vivo removal of IgE after in vitro screening of matrix (Sepharose and tresyl-activated Toyopearl) and ligand (monospecific rabbit polyclonal anti-IgE antiserum and monoclonal antibodies (Abs) or their Fab fragments). Specific adsorptive capacity (SAC) for IgE was maximal in Sepharose-based IA with both types of Abs. Fab-containing IA on Sepharose retained 70-90% of the SAC of native Ab-containing IA. Toyopearl-based IA showed comparable SAC under static conditions but worked unsatisfactorily under continuous flow conditions. To assess the complement-activating capacity (CAC) of IA in vitro anaphylatoxin (C3a, C4a, C5a) generation was applied. CAC was directly related with the amount of immobilized Ab ligand, without depending on Ab specific activity. Fab-containing IA showed more CAC than native Ab-containing IA, and polyclonal IA more than monoclonal IA. Therefore, IA for IgE apheresis were prepared from native monoclonal Abs and CNBr-activated Sepharose CL 4B under aseptic conditions and packed into a glass column. This IA was used in 17 clinical IgE apheresis treatments of five atopic asthma patients. No substantial side effects were observed; in vivo IA effectively removed IgE from plasma (83 to 98%).
Institute of Pulmonology, Cardiology Research Centre, Moscow, USSR.
Y S
YS
Lebedin
V D
VD
Gorchakov
E N
EN
Petrova
A G
AG
Kobylyansky
L A
LA
Raudla
A R
AR
Tatarsky
E V
EV
Bobkov
I Y
IY
Adamova
R G
RG
Vasilov
E L
EL
Nasonov
D000328:Adult; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D001781:Blood Component Removal / Q000379:methods; D006801:Humans; D007073:Immunoglobulin E; D007163:Immunosorbent Techniques; D007164:Immunosorbents; D008297:Male; D010477:Perfusion; D010949:Plasma; D011108:Polymers
D007164:Immunosorbents; D011108:Polymers; D007073:Immunoglobulin E; C058606:Toyopearl 650